A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

COVID-19 Clinical Trial

Official title:

A Phase 3b/4 Randomised Trial of 3 Doses of Protein-based Covid-19 Vaccine (SpikoGen)

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05279456
• Other study ID #: AUST-C19-P3/4
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: August 15, 2022
• Est. completion date: June 30, 2024

Study information

• Verified date: April 2024
• Source: Vaxine Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will determine the immunogenicity of Spikogen in vaccine naïve individuals. Spikogen will be administered as two doses 1 month apart with a third booster dose either 1 or 3 months after the second dose. This study will provide key data on SARS-CoV-2 antibody responses.

Description:

The SARS-CoV-2 outbreak has caused millions of deaths globally. It has a particularly high mortality rate in elderly people and those with chronic disease where mortality rates can be as high as 20-30%. SARS-COV-2 vaccines remain a key priority to help fight the current pandemic. COVID-19 vaccines prevent symptomatic infection and may help reduce virus transmission. Spikogen® vaccine, also known as Covax-19™ in Australia, is an adjuvanted recombinant protein Covid-19 vaccine has recently been approved by the Iranian FDA for emergency use in Iran in adults as a primary vaccine course and booster dose, after meeting its primary efficacy endpoint in a Phase 3 trial in 16,876 participants randomised 3:1 to receive Spikogen vaccine or saline placebo via two intramuscular doses 3 weeks apart where Spikogen vaccine demonstrated significant protection against serious infection with the delta variant. Approximately 5-10% of the broader Australian population and an even higher proportion of the indigenous populations remains unvaccinated despite current availability of these vaccines. One reason is that some people have medical contraindications to the current vaccines, such as serious allergies to the vaccine components such as polyethyleneglycol (PEG) in the mRNA vaccines.

Spikogen vaccine is made using a recombinant protein approach with the SARS-CoV-2 spike protein synthesized in an insect cell line grown in broth. Insect cell expression of recombinant protein is a well-established vaccine manufacturing approach. Spikogen vaccine also contains a unique Australian developed adjuvant called Advax-CpG55.2, which is added to the spike protein to make the vaccine more effective. AdvaxCpG55.2 has two components, one a natural plant sugar called inulin, and the second a short synthetic oligonucleotide polymer, known as CpG55.2 oligonucleotide.

Spikogen vaccine is designed to protect against SARS-CoV-2 infection. It has been shown to be effective against infection in hamster, ferret and monkey SARS-CoV-2 infection models.

This study will determine the immunogenicity of Spikogen in vaccine-naïve individuals. Spikogen will be administered as two doses 31 month apart with a third booster dose given either 1 or 3 months after the second dose.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 39
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Able to provide written informed consent

• Males or females* 18 years of age or older

• Understand and are likely to comply with planned study procedures and be available for all study visits.

• Have not previously had a Covid-19 vaccine and do not intend to have a non-study Covid-19 vaccine within the next 6 months

Exclusion Criteria:

• History of Covid-19 vaccination.

• History of serious vaccine allergy.

• Pregnancy1

• Have received an experimental agent within 30 days prior to the study vaccination or expect to receive another experimental agent during the trial reporting period.

• Any medical, social or mental condition which, in the opinion of the investigator, would be detrimental to the subjects or the study.

Related Conditions & MeSH terms

• COVID-19

Intervention

Biological:
• Advax-CpG55.2 adjuvanted recombinant spike protein
recombinant SARS-CoV-2 spike protein formulated with Advax-CpG55.2 adjuvant

Locations

Country	Name	City	State
Australia	ARASMI	Adelaide	South Australia

Sponsors (2)

Lead Sponsor	Collaborator
Vaxine Pty Ltd	Australian Respiratory and Sleep Medicine Institute

Country where clinical trial is conducted

Australia, 

References & Publications (1)

Li L, Honda-Okubo Y, Huang Y, Jang H, Carlock MA, Baldwin J, Piplani S, Bebin-Blackwell AG, Forgacs D, Sakamoto K, Stella A, Turville S, Chataway T, Colella A, Triccas J, Ross TM, Petrovsky N. Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection. Vaccine. 2021 Sep 24;39(40):5940-5953. doi: 10.1016/j.vaccine.2021.07.087. Epub 2021 Aug 3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Antibody kinetics	rate of change in peak to trough serum spike protein antibody levels over time in each group stratified by baseline antibody positivity	2-4 weeks post first, second and third immunisation and at study completion
Other	Age effects on seroconversion	Proprotion seroconverting to spike protein antibodies analysed by age and gender	2-4 weeks post first, second and third immunisation and at study completion
Other	Age effects on antibody levels	Geometric Mean Titers of spike protein antibodies in participants by age and gender	2-4 weeks post first, second and third immunisation and at study completion
Other	immune-deficiency effects on seroconversion	Proportion of subjects seroconverting to spike protein antibodies in participants with or without immune-deficiency	2-4 weeks post first, second and third immunisation and at study completion
Other	immune-deficiency effects on antibody levels	Geometric Mean Titers (GMT) of spike protein antibodies in participants with or without immune-deficiency	2-4 weeks post first, second and third immunisation and at study completion
Primary	First dose Seroconversion	Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity	2-4 weeks post first immunisation
Primary	Second dose Seroconversion	Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity	2-4 weeks post second immunisation
Primary	Third Dose Seroconversion	Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity	2-4 weeks post third immunisation
Primary	Final Seroconversion	Proportion of subjects in each group stratified by baseline antibody positivity seroconverting to spike protein antibody positivity	through study completion, an average of 7 months
Primary	First Dose GMT	Spike protein antibody Geometric Mean Titers (GMT) in each group stratified by baseline antibody positivity	2-4 weeks post first immunisation
Primary	Second Dose GMT	Spike protein antibody Geometric Mean Titers (GMT) in each group stratified by baseline antibody positivity	2-4 weeks post second immunisation
Primary	Third Dose GMT	Spike protein antibody Geometric Mean Titers (GMT)in each group stratified by baseline antibody positivity	2-4 weeks post third immunisation
Primary	Final GMT	Spike protein antibody Geometric Mean Titers (GMT)in each group stratified by baseline antibody positivity	through study completion, an average of 7 months
Primary	First Dose Adverse events (AE)	AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity	7 days post first immunisation
Primary	Second Dose Adverse events (AE)	AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity	7 days post second immunisation
Primary	Third Dose Adverse events (AE)	AE occurring within 7 days of immunisation in each group stratified by baseline antibody positivity	7 days post third immunisation
Primary	Serious adverse events (SAE)	Number of Serious adverse events (SAE) occurring within study period in each group stratified by baseline antibody positivity	through study completion, an average of 7 months
Secondary	First dose Vaccine efficacy	Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity	From 2 weeks post-first dose to 2 weeks after second dose
Secondary	Second dose Vaccine efficacy	Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity	From 2 weeks post-second dose to 2 weeks after third dose
Secondary	Third dose Vaccine efficacy	Proportion of Covid-19 infections in trial participants in each group stratified by baseline antibody positivity	From 2 weeks post-third dose through study completion, an average of 7 months
Secondary	Total Covid-19 infections	Proportion of breakthrough Covid-19 infections in trial participants in each group stratified by baseline antibody positivity	From first vaccine dose through study completion, an average of 7 months
Secondary	Seroconversion against variants of concern	Serum spike protein antibody seroconversion rates against each SARS-CoV-2 variant of concern in trial participants in each group stratified by baseline antibody positivity	2-4 weeks post first, second and third immunisation and at study completion
Secondary	GMT against variants of concern	Geometric mean serum spike protein antibodies against SARS-CoV-2 variants in trial participants in each group stratified by baseline antibody positivity	2-4 weeks post first, second and third immunisation and at study completion

External Links

•   Link to company website